Literature DB >> 12407132

Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

W Brumfitt1, M R J Salton, J M T Hamilton-Miller.   

Abstract

OBJECTIVE: We have sought ways to circumvent resistance, by combining nisin with other antibiotics known to target bacterial cell wall biosynthesis.
METHODS: Twenty strains each of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) were tested in vitro by standardized methods against nisin alone and combined with bacitracin, ramoplanin and chloramphenicol.
RESULTS: Ramoplanin was the most potent compound, and bacitracin had the least activity. Two-way synergy was observed with nisin and ramoplanin. However, chloramphenicol was clearly antagonistic to the activity of nisin.
CONCLUSIONS: Observations of synergy between nisin and ramoplanin against MRSA and VRE offer a promising approach to the concept of combining nisin with inhibitors of cell wall peptidoglycan. Further investigations are needed in order to develop this approach as a clinical possibility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407132     DOI: 10.1093/jac/dkf190

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

1.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  The continuing story of class IIa bacteriocins.

Authors:  Djamel Drider; Gunnar Fimland; Yann Héchard; Lynn M McMullen; Hervé Prévost
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

Review 3.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

4.  Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.

Authors:  Paul D Cotter; Lorraine A Draper; Elaine M Lawton; Olivia McAuliffe; Colin Hill; R Paul Ross
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

Review 5.  Bioengineering of the model lantibiotic nisin.

Authors:  Des Field; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Bioengineered       Date:  2015-05-13       Impact factor: 3.269

6.  A central composite rotatable design (CCRD) approach to study the combined effect of antimicrobial agents against bacterial pathogens.

Authors:  Fernanda Godoy Santos; Layanne Andrade Mendonça; Hilário Cuquetto Mantovani
Journal:  World J Microbiol Biotechnol       Date:  2015-06-17       Impact factor: 3.312

Review 7.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

8.  Insights into Lantibiotic Immunity Provided by Bioengineering of LtnI.

Authors:  Lorraine A Draper; Lucy H Deegan; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

9.  ABC Exporters in Pathogenesis: Role of Synthetic Anti-Microbial Peptides.

Authors:  Ritika Kabra; Shailza Singh
Journal:  Protein J       Date:  2020-10-17       Impact factor: 2.371

10.  Entianin, a novel subtilin-like lantibiotic from Bacillus subtilis subsp. spizizenii DSM 15029T with high antimicrobial activity.

Authors:  Sebastian W Fuchs; Thorsten W Jaskolla; Sophie Bochmann; Peter Kötter; Thomas Wichelhaus; Michael Karas; Torsten Stein; Karl-Dieter Entian
Journal:  Appl Environ Microbiol       Date:  2011-01-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.